John Hendrix has been named Program Director, Member and Vendor Relations for SAFE-BioPharma Association, the non-profit association that created and manages the SAFE-BioPharma™ digital identity and digital signature standard for the pharmaceutical and healthcare industries. In his new position, Mr. Hendrix has responsibility for attracting members and vendor-partners to the SAFE-BioPharma community. He also will participate in marketing digital identity assurance and digital signature services among SAFE-BioPharma member companies, comprising many of the world’s largest biopharmaceutical companies. “In an effort to make their businesses more efficient and cost effective, our member companies are incorporating the SAFE-BioPharma digital standard into their daily operations. John Hendrix has the necessary industry knowledge and sales skills to stimulate broader and deeper use of the standard,” said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. The SAFE-BioPharma digital identity and signature standard was established by the biopharmaceutical industry to help mitigate legal, regulatory and other business risk associated with electronic transactions. It provides users with a secure, enforceable and regulatory compliant way to verify identities of parties involved in electronic transactions, and to apply their digital signatures to electronic documents. By using SAFE-BioPharma digital signatures, companies are able to dispense with paper originals and other cumbersome forms of backup. Mr. Hendrix is a seasoned marketing management professional with a strong understanding of the pharmaceutical industry. He most recently served as a contract marketing executive with Schering Plough and with Merck. Prior to that he held a variety of strategic and product marketing positions in the life sciences industry. Mr. Hendrix earned an MBA in management and an MS in international business from Seton Hall University. He also earned an MS in engineering from New Jersey Institute of Technology, and a BBA in management and a BBS in engineering technology from Francis Marion University. About SAFE-BioPharma Association SAFE-BioPharma Association is the non-profit association that created and manages the SAFE™ digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability between disparate information systems by providing a secure, enforceable and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE’s vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association’s members include Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, visit www.safe-biopharma.org.